Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 6
2005 1
2006 4
2007 4
2008 5
2009 4
2010 9
2011 8
2012 6
2013 10
2014 12
2015 12
2016 18
2017 13
2018 16
2019 18
2020 23
2021 30
2022 32
2023 30
2024 24
2025 26
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Results by year

Filters applied: . Clear all
Page 1
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M. Carbone DP, et al. Among authors: lee a. J Immunother Cancer. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189. J Immunother Cancer. 2024. PMID: 38346853 Free PMC article. Clinical Trial.
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1.
Peters S, Regan MM, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Brahmer JR, Penrod JR, Li J, Tracy L, Yuan Y, Bushong J, Lee A, Eccles LJ, Ray S, Ramalingam SS. Peters S, et al. Among authors: lee a. J Thorac Oncol. 2025 Oct;20(10):1505-1516. doi: 10.1016/j.jtho.2025.05.019. Epub 2025 Jun 3. J Thorac Oncol. 2025. PMID: 40473108 Free article. Clinical Trial.
Predicting pKa.
Lee AC, Crippen GM. Lee AC, et al. J Chem Inf Model. 2009 Sep;49(9):2013-33. doi: 10.1021/ci900209w. J Chem Inf Model. 2009. PMID: 19702243 Review.
Supraventricular tachycardia with double trouble.
Howell SJ, Lee A, Scheinman M. Howell SJ, et al. Among authors: lee a. Heart Rhythm. 2022 Sep;19(9):1569-1570. doi: 10.1016/j.hrthm.2021.10.024. Epub 2021 Oct 29. Heart Rhythm. 2022. PMID: 34757191 No abstract available.
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
O'Byrne K, Popoff E, Badin F, Lee A, Yuan Y, Lozano-Ortega G, Eccles LJ, Varol N, Waser N, Penrod JR, Goring S. O'Byrne K, et al. Among authors: lee a. Lung Cancer. 2023 Mar;177:11-20. doi: 10.1016/j.lungcan.2023.01.006. Epub 2023 Jan 11. Lung Cancer. 2023. PMID: 36669321 Free article.
280 results